@prefix orcid: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix ns2: .
@prefix ns1: .
@prefix prov: .
@prefix ns3: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo .
}
sub:assertion {
ns1:reduce .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-12-16T19:44:14.511880"^^xsd:dateTime;
prov:wasGeneratedBy "S&T TWOC project version 2" .
sub:version prov:value "2"^^xsd:integer .
rdf:OBJECT rdfs:label "the incidence of PONV ( 3.05 % , 22/721 )" .
rdf:OBJECT-POSITION rdfs:label "16"^^xsd:integer .
rdf:PREDICATE rdfs:label "reduced" .
rdf:PREDICATE-POSITION rdfs:label "[67]" .
rdf:SUBJECT rdfs:label "Results dexamethasone and 5-HT3 antagonist combination" .
rdf:SUBJECT-POSITION rdfs:label "28"^^xsd:integer .
rdfs:ABSTRACT-UID ns2:50 "d2wau7rl" .
rdfs:SENTENCE rdfs:label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." .
rdfs:TRIPLE-UID ns3:d2wau7rl-TRIPLE-ABSTRACT-5 "d2wau7rl-TRIPLE-ABSTRACT-5" .
rdfs:label "ht3" .
rdfs:label "ponv" .
}
sub:pubInfo {
sub:assertion prov:wasDerivedFrom .
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
npx:hasSignature "eg+ml+d12k1Uahy7bhiYeDR6W043PcKHf1mLln/wikd6jOcnBOt4hhAxP89dsNjMI4q9uQNsVwq8MsLxzP5SezFMT423wsFQKoSn3r2wA82y1EWWXxhoLc3KgVroAC4c+nIAugk/l+pxQWQbi8j4KrqN6N87vp0/Pf8iVF6rOlM=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2021-12-16T19:44:14.511880"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}